-
GeoVax to Raise Approximately $6 Million of Gross Proceeds in Public Offering
Atlanta, GA, July 1, 2025 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases,…
-
GeoVax Announces Issuance of Patent Covering Novel Vaccine Construct for Preventing Malaria Infection
Patent Supports Multi‑Antigenic VLP-MVA Vaccine Design for Products Used Against Endemic and Emerging Infectious Diseases ATLANTA, GA, June 25, 2025 – GeoVax Labs,…
-
GeoVax Comments on FDA Approval of Keytruda® in Head and Neck Cancer, Underscoring Potential for Gedeptin® Combination Therapy
Supports Advancement of GeoVax’s Phase 2 Gedeptin® Trial in Recurrent Head and Neck Cancer ATLANTA, GA, June 24, 2025 – GeoVax Labs, Inc. (Nasdaq:…
-
GeoVax Highlights Positive Immune Response Results From GEO-CM04S1 in CLL Patients at the European Hematology Association 2025 Meeting
GEO-CM04S1 Demonstrates Superior T Cell Responses Compared to mRNA Vaccine in Phase 2 Trial Among Immunocompromised Patients ATLANTA, GA, June 17, 2025 – GeoVax…
-
GeoVax Receives Favorable European Regulatory Guidance Supporting Streamlined Development Pathway for GEO-MVA
Confirms Single Phase 3 Immuno-Bridging Trial Sufficient to Evaluate Efficacy and to Support a Marketing Authorization Application (MAA) For Vaccination against Mpox and…
-
GeoVax to Participate in BIO International Convention 2025
ATLANTA, GA – June 12, 2025 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies, today announced that…
-
GeoVax Responds to WHO’s Fourth Declaration of Mpox as a Global Public Health Emergency
GEO-MVA Provides Potential Opportunity to Expand Mpox Vaccine Supply Amid Growing U.S. and Global Clade 1 Threat ATLANTA, GA – June 11, 2025…
-
GeoVax Announces Upcoming Presentation at the European Hematology Association 2025 Congress Highlighting Positive Immune Response Data for GEO-CM04S1 in CLL Patients
ATLANTA, GA, June 10, 2025 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies against infectious diseases and solid tumors,…
-
GeoVax Highlights Broad Cross-Protective Immunity of Multi-Antigen COVID-19 Vaccine Candidates at Keystone Symposia
Preclinical Studies Demonstrate Durable Protection Against SARS-CoV-2 Variants, Including Omicron XBB.1.5, Driven by T-Cell Responses ATLANTA, GA, June 9, 2025 – GeoVax Labs,…
-
GeoVax to Showcase Innovative COVID 19 Vaccine Data at the Keystone Symposia on Vaccinology
Data from Two Key Studies Highlight Cross‑Reactivity and Broad‑Spectrum Immunity of GEO-CM04S1 and GeoVax Multi-Antigen Vaccine Technology ATLANTA, GA – June 4, 2025 –…
-
GeoVax Congratulates Bipartisan Senate Action to Onshore Critical Medical Manufacturing
Highlights Broad National Support for Domestic Vaccine Resilience and Role of MVA Platform in Public Health Preparedness ATLANTA, GA – May 29, 2025 –…
-
GeoVax Commends FDA’s Shift to Risk-Based COVID-19 Vaccination Guidance
Highlights Critical Role of Multi-Antigen GEO-CM04S1 in Protecting Vulnerable Populations ATLANTA, GA, May 27, 2025 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage…